Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Jonasch

Showing results (11-20 of 271) with videos related to

Pageof 28
Sort By:
Current Oncology Reports|April 2, 2011
Have molecularly targeted therapies improved overall survival in renal cell carcinoma?Michel Choueiri, Eric Jonasch
The Lancet. Oncology|July 3, 2025
Real-world challenges and considerations in treating von Hippel-Lindau disease with HIF-2α inhibitors - Authors' replyRamaprasad Srinivasan, Eric Jonasch
Lancet (London, England)|May 14, 2019
Durable complete response in renal cell carcinoma clinical trialsPatrick G Pilié, Eric Jonasch
Journal of the National Comprehensive Cancer Network : JNCCN|September 6, 2014
Genetic kidney cancer syndromesThai H Ho, Eric Jonasch
Kidney Cancer (Clifton, Va.)|October 19, 2018
Systematic Review: Perioperative Systemic Therapy for Metastatic Renal Cell CarcinomaPatrick G Pilié, Eric Jonasch
Journal of the National Comprehensive Cancer Network : JNCCN|June 9, 2012
Ten years of progress in renal cell carcinomaEric Jonasch, Robert J Motzer
Targeted Oncology|July 14, 2010
Targeted therapy for locally advanced renal cell carcinomaEric Jonasch, Nizar M Tannir
Journal of Oncology Practice|May 13, 2016
Treatment of Relapsed Germ Cell Tumors: Time For Something New?Matthew T Campbell, Eric Jonasch
Journal of the National Comprehensive Cancer Network : JNCCN|May 27, 2016
NCCN Evidence BlocksRobert W Carlson, Eric Jonasch
Future Oncology (London, England)|June 22, 2006
Targeting von Hippel-Lindau syndrome: the future is nowSurena F Matin, Eric Jonasch
Pageof 28

Showing results (11-20 of 271) with videos related to

Sort By:
Pageof 28
Current Oncology Reports|April 2, 2011
Have molecularly targeted therapies improved overall survival in renal cell carcinoma?Michel Choueiri, Eric Jonasch
The Lancet. Oncology|July 3, 2025
Real-world challenges and considerations in treating von Hippel-Lindau disease with HIF-2α inhibitors - Authors' replyRamaprasad Srinivasan, Eric Jonasch
Lancet (London, England)|May 14, 2019
Durable complete response in renal cell carcinoma clinical trialsPatrick G Pilié, Eric Jonasch
Journal of the National Comprehensive Cancer Network : JNCCN|September 6, 2014
Genetic kidney cancer syndromesThai H Ho, Eric Jonasch
Kidney Cancer (Clifton, Va.)|October 19, 2018
Systematic Review: Perioperative Systemic Therapy for Metastatic Renal Cell CarcinomaPatrick G Pilié, Eric Jonasch
Journal of the National Comprehensive Cancer Network : JNCCN|June 9, 2012
Ten years of progress in renal cell carcinomaEric Jonasch, Robert J Motzer
Targeted Oncology|July 14, 2010
Targeted therapy for locally advanced renal cell carcinomaEric Jonasch, Nizar M Tannir
Journal of Oncology Practice|May 13, 2016
Treatment of Relapsed Germ Cell Tumors: Time For Something New?Matthew T Campbell, Eric Jonasch
Journal of the National Comprehensive Cancer Network : JNCCN|May 27, 2016
NCCN Evidence BlocksRobert W Carlson, Eric Jonasch
Future Oncology (London, England)|June 22, 2006
Targeting von Hippel-Lindau syndrome: the future is nowSurena F Matin, Eric Jonasch
Pageof 28